Market
Synopsis of Global Paroxysmal Atrial Tachycardia Market
Market Scenario
Paroxysmal atrial tachycardia is a type of atrial arrhythmia and is also known as paroxysmal supraventricular tachycardia (PSVT). PAT increases heart rate from 60 to 100 beats per minute (bpm) to between 130 and 230 bpm with infants demonstrating substantial heart rate greater than 220 bpm. Symptoms of PAT may include palpitations, lightheaded, sweating, shortness of breath, chest pain and others. PAT is not a life-threatening situation but in rare cases, PAT may cause unconsciousness, congestive heart failure, cardiomyopathy and cardiac arrest. Having other heart issues such heart attacks or valve disease increase risk for PAT.
Market Scenario
Paroxysmal atrial tachycardia is a type of atrial arrhythmia and is also known as paroxysmal supraventricular tachycardia (PSVT). PAT increases heart rate from 60 to 100 beats per minute (bpm) to between 130 and 230 bpm with infants demonstrating substantial heart rate greater than 220 bpm. Symptoms of PAT may include palpitations, lightheaded, sweating, shortness of breath, chest pain and others. PAT is not a life-threatening situation but in rare cases, PAT may cause unconsciousness, congestive heart failure, cardiomyopathy and cardiac arrest. Having other heart issues such heart attacks or valve disease increase risk for PAT.
The risk
factors include alcohol, caffeine, nicotine, psychological stress, and
Wolff-Parkinson-White syndrome. PAT occurs when electrical signals starting in
the heart’s atria fire irregularly which affects the electrical signals
transmitted from the sino-atrial node. This irregular beating prevents your
heart from having enough time to fill with blood before pumping blood resulting
in the body not receiving enough oxygenated blood. Women are at a higher risk
for PAT than men. PAT has an incidence rate of approximately 2 per 1000 people.
The cause of PAT are unknown but
risk factors include alcohol, caffeine, nicotine, psychological stress, and
Wolff-Parkinson-White syndrome. PAT occurs when electrical signals starting in
the heart’s atria fire irregularly which affects the electrical signals
transmitted from the sinoatrial node. This irregular beating prevents your
heart from having enough time to fill with blood before pumping blood resulting
in the body not receiving enough blood or oxygen. Women are at a higher risk
for PAT than men.
The market drivers for global
paroxysmal atrial tachycardia market are rise in demand due to growing older
population, increasing screening, greater emphasis on cardiac treatment,
urgency of the paroxysmal atrial tachycardia treatment, rise in risk factors
and others. The market restraints are the complications such as risk of
bleeding, infections, pain, especially during surgery, high cost of paroxysmal
atrial tachycardia treatment, lack of cardiac care infrastructure, and lack of
focus on other diseases by the developing regions and others.
The
global paroxysmal atrial tachycardia market is expected to reach USD 10.7
billion by 2023, and the market is projected to grow at a CAGR of ~ 6.5 %
during the forecast period 2017-2023.
Segments
The global paroxysmal atrial tachycardia market has been segmented on the basis of types, condition, diagnosis, drugs, surgery and end user.
The global paroxysmal atrial tachycardia market has been segmented on the basis of types, condition, diagnosis, drugs, surgery and end user.
Based on
the types, the market has been segmented as AV nodal re-entrant tachycardia
(AVNRT), AV reciprocating tachycardia (AVRT), and paroxysmal atrial
tachycardia.
Based on
the diagnosis, the market has been segmented as electrocardiogram (ECG),
echocardiogram, blood tests, and electrophysiology study (EPS) and others.
Based on
the treatment, the market has been segmented as calcium channel blockers,
digoxin, beta-blockers, anti-arrhythmic medications, surgical ablation and
others.
Based on
the end user, the market has been segmented as hospitals and clinics, research
and academics and others.
Regional Analysis
The Americas accounts for a significant market
share owing to high expenditure on the health care especially of the U.S. and
Canada. Additionally, the greater number of cardiac procedures due to greater
healthcare penetration in the U.S. and Canada drives the market. The high
concentration of the major hospitals in the developed countries of this region
coupled with good reimbursement rates is adding fuel to the market growth.
Moreover, the large share of cardiac procedures especially the cardiac surgery
treatment in the returns of hospitals favors the market. The large number of
pharmaceutical companies in the U.S. is also a cause for the faster development
of paroxysmal atrial tachycardia market in the U.S.. Advancements of
microsurgery in developed regions such as the U.S. and Europe is a strong
driver of the market.
Asia Pacific region is expected to grow rapidly;
China and India are likely to lead this market due to fast growing healthcare
sector and large unmet needs over the forecast period. South East Asian
countries such as China, India, and Malaysia are projected to contribute highly
to the market growth. The growing penetration of healthcare industry in the
Asia Pacific region is expected to drive the future paroxysmal atrial
tachycardia market in the region. However the low expenditure on cardiac and
eye care coupled with the lack of insurance penetration in the developing
regions is a dent on the market.
Gulf nations such as Saudi Arabia and the UAE are
estimated to drive the Middle East & African market. Other Middle East
nations to watch out for are Kuwait, Jordan, Egypt and Iran. The African region
is expected to witness a poor growth owing to poor economic and political conditions,
and poor healthcare development. Other regions are expected to be laggards due
to poor social development and tribal identities such as sub Saharan Africa.
The focus of the governments of poor countries on fulfilling basic healthcare
relegates the paroxysmal atrial tachycardia market to the background which
hampers the development of the market.
Key
Players
Some of the key players profiled in the report are Abbott Laboratories, Reliant Pharmaceuticals, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, GlaxoSmithKline plc, GE Healthcare, Glenmark Pharmaceuticals, Koninklijke Philips N.V., ANI Pharmaceuticals, Inc., Medtronic, Inc., Microport Scientific Corporation, St. Jude Medical, Inc., and Siemens AG and others.
Some of the key players profiled in the report are Abbott Laboratories, Reliant Pharmaceuticals, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, GlaxoSmithKline plc, GE Healthcare, Glenmark Pharmaceuticals, Koninklijke Philips N.V., ANI Pharmaceuticals, Inc., Medtronic, Inc., Microport Scientific Corporation, St. Jude Medical, Inc., and Siemens AG and others.
Table Of Content
1. Report Prologue
2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
5. Market Factor Analysis
5.1 Porters Five Forces Analysis
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
About
US:
Market
Research Future (MRFR), enable customers to unravel the complexity of various
industries through Cooked Research Report (CRR), Half-Cooked Research Reports
(HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market
Research & Consulting Services.
Contact
Us:
Market
Research Future
Office
No. 528, Amanora Chambers
Magarpatta
Road, Hadapsar,
Pune
- 411028
Maharashtra,
India
Phone:
+1 646 845 9312
Email:
sales@marketresearchfuture.com
No comments:
Post a Comment